FDA Adverse Event Malfunction Summary report: N

PIPELINE

MDR report key: 9843413 · Received March 17, 2020

Report

Report Number
2029214-2020-00244
Event Type
Malfunction
Date Received
March 17, 2020
Date of Event
October 1, 2015
Report Date
March 17, 2020
Manufacturer
MICRO THERAPEUTICS, INC. DBA EV3
Product Code
OUT
PMA / PMN Number
P100018.S004
Product Problem
Yes
Report Source
Manufacturer report
Reporter Location
CH
Reporter Occupation
OTHER

Narratives

Additional Manufacturer Narrative · 1

IF INFORMATION IS PROVIDED IN THE FUTURE, A SUPPLEMENTAL REPORT WILL BE ISSUED.

Description of Event or Problem · 1

LV X, JIANG C, WU Z, JIANG W, WANG G. COMPLEX CEREBRAL ANEURYSMS: INTRA-LUMINAL RECONSTRUCTION USING PIPELINE FLOW-DIVERTING STENT AND THE OBLITERATION MECHANISM. THE NEURORADIOLOGY JOURNAL. DECEMBER 2019:1971400919894879. DOI:10.1177/1971400919894879. MEDTRONIC RECEIVED A REPORT THROUGH LITERATURE TO DOCUMENT THE CLINICAL AND ANGIOGRAPHIC OUTCOMES IN 80 PATIENTS WHO WERE TREATED WITH THE PIPELINE FLOW-DIVERTING STENT. FORTY-FIVE PATIENTS WERE WOMEN AND 35 WERE MEN, WITH A MEAN AGE OF 52 YEARS. THE STUDY TOOK PLACE BETWEEN OCTOBER 2015 AND OCTOBER 2019, 80 PATIENTS WITH 90 COMPLEX BLOOD BLISTER¿LIKE, AND RECURRENT SIDE-WALL CEREBRAL ANEURYSMS TREATED WITH THE PIPELINE WERE REVIEWED. FORTY-ONE ANEURYSMS WERE LARGE OR GIANT, 41 WERE SMALL, FOUR WERE RECURRENT SIDE-WALL ANEURYSMS, AND FOUR WERE BLOOD BLISTER¿LIKE ANEURYSMS. IN SEVEN PATIENTS, A SECOND PFS WAS NECESSARY TO COVER THE ANEURYSM NECK. AMONG THEM, COILS WERE PLACED IN ADDITION TO THE PFS IN 31 ANEURYSMS. 82 OF 83 ANEURYSMS WERE OCCLUDED FOR A TOTAL OCCLUSION RATE OF 98.8% THERE WAS NO PATIENT RELATED MORBIDITY. MORTALITY OCCURRED IN ONE PATIENT DUE TO THROMBOLYSIS FROM THROMBUS FORMATION IN THE LEFT ICA, RESULTING IN AN IPSILETARAL REMOTE INTRAPARENCHYMAL HEMATOMA.

Devices

Seq Brand Generic Product Code Manufacturer Model Lot UDI-DI
306186 PIPELINE INTRACRANIAL ANEURYSM FLOW DIVERTER OUT MICRO THERAPEUTICS, INC. DBA EV3 NV UNK PIPELINE UNKNOWN

Patients

Seq Age Sex Outcome Treatment
1 52 YR